clinical trial · NCT06122649
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
Amgen·phase3·completed·n = 203
Plaque PsoriasisapremilastPlacebo
brief summary
The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with placebo in Chinese participants with moderate to severe PsO
started
Nov 27, 2023
primary completion
Feb 28, 2025
completion
Dec 5, 2025
last updated
Jan 5, 2026
official title
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Apremilast 30 mg Twice Daily in Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol